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Abstract
Rapid progress in identifying disease biomarkers has increased the importance of creating high-
performance detection technologies. Over the last decade, the design of many detection platforms 
has focused on either the nano or micro length scale. Here, we review recent strategies that 
combine nano- and microscale materials and devices to produce large improvements in detection 
sensitivity, speed and accuracy, allowing previously undetectable biomarkers to be identified in 
clinical samples. Microsensors that incorporate nanoscale features can now rapidly detect disease-
related nucleic acids expressed in patient samples. New microdevices that separate large clinical 
samples into nanocompartments allow precise quantitation of analytes, and microfluidic systems 
that utilize nanoscale binding events can detect rare cancer cells in the bloodstream more 
accurately than before. These advances will lead to faster and more reliable clinical diagnostic 
devices.
Increasingly, advances in medicine rely on understanding the multi-molecular causes, 
effects and signatures of diseases. Personalized therapies targeted to highly specific disease 
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sub-states now leverage insights into the molecular origins and signatures of these 
illnesses1,2. As therapeutic regimes become increasingly sophisticated and targeted, many 
diseases are now more treatable than before.
However, many approaches to diagnostic testing remain decades — and in some cases 
centuries — old3. One of the major impediments to effective diagnosis is the slow 
turnaround of most diagnostic techniques. Using culture to diagnose fast-spreading 
infectious diseases, for example, can take days to weeks4. Furthermore, poor sensitivity in 
many approaches means that for some diseases detection is possible only at the advanced 
stages, where they are difficult to treat5. These issues weigh on already-strained health care 
systems and hinder the delivery of optimal patient outcomes. The economic burden 
associated with the limitations of present-day diagnostic paradigms contributes to the 
unsustainable health care systems of many countries in the developed world, and also limits 
adoption of new treatments in the developing world6,7. Many of the global health crises that 
burden the developing world will benefit substantially from implementation of user-friendly, 
inexpensive diagnostic tools to deliver effective care to areas where sophisticated lab 
facilities are not available.
The last decade has yielded breakthroughs that are poised to transform disease diagnosis 
based on molecular signatures. In particular, the latest generation of devices addresses three 
distinct and physically important length scales that impact the detection process: the 
nanoscale dimensions of biological analytes; the micrometre length scale of biomolecular 
diffusion; and the macroscopic scale of clinical samples that contain millilitres of fluid to be 
processed. In this Review, we summarize the challenges related to achieving clinically 
relevant levels of performance with diagnostic technologies, and we discuss recent progress 
in the development of advanced detection systems through the lens of multi-length-scale 
integration. We highlight several new high-performance systems that have achieved record-
breaking levels of speed, sensitivity and accuracy. We also discuss new frontiers in this field 
and identify challenges that remain.
Critical length scales for biomolecular detection
The detection of biological molecules involves phenomena occurring across different length 
scales (Fig. 1). For example, the regime of biomolecular recognition lies between 1 nm and 
10 nm. The binding regions of nucleic acids having sequence-specific roles in biology are in 
the range of 20 base pairs and above, corresponding to 6 nm and greater. Protein–protein 
interactions also occur on the nanometre length scale.
Between 10 μm and 100 μm corresponds to the regime of molecular diffusion in solution. 
The size and shape of the biomolecular analytes of interest, combined with physiological 
temperatures, dictate that in the minutes-to-hours timescale appropriate for rapid 
biomolecular detection, typical large biological analyte molecules can diffuse 10–100 μm.
The regime of clinical sample size is millimetres to centimetres (or microlitres to millilitres). 
For many applications where the analyte of interest is rare, it is important to sample large 
volumes. The detection of bacterial pathogens to diagnose bloodstream infections and the 
analysis of circulating tumour cells (CTCs) are two examples of such applications where 
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only a few cells may be present in a millilitre of blood, necessitating that several millilitres 
must be sampled.
Over the last two decades, the increasing availability of bottom-up and top-down strategies 
for generating nanomaterials8,9, combined with expanded methodologies that allowed 
conjugation of biological receptors, have prompted a significant focus on miniaturized 
detectors10. Furthermore, microfluidic devices have become increasingly sophisticated11. 
These efforts have produced many examples of high-performance sensing systems, and 
several microfluidic platforms have been commercialized for research applications.
Early achievements in this area also highlighted the limitations of these approaches when 
used in isolation. While the ability of nanoscale detectors to detect biological molecules with 
excellent sensitivity became well documented, it was recognized that sensors with very 
small surface areas could not efficiently and rapidly capture and detect large, slow-moving 
analyte molecules within clinical samples12,13. Microfluidic devices that automate the steps 
required for biomolecular detection using methods such as the polymerase chain reaction or 
immunoassays served to complement, rather than supplant, diagnostic technologies that 
offer complete solutions in themselves.
Recently, combining microscale systems with nanomaterial-based strategies has permitted 
new types of biomolecular analysis to be developed and high levels of sensitivity to be 
validated with clinical specimens. Furthermore, using microscale devices to divide large 
samples into nanoscale aliquots has provided new ways to quantitate biomolecules. 
Moreover, microscale devices can leverage nanoscale binding events to sense rare analytes 
and cells at parts per million levels. In this Review, we explore these concepts and their 
impact on advances in protein biomarker analysis, nucleic acid detection and rare-cell 
analysis.
Performance challenges
To be effective at analysing clinical samples, biomolecular detection systems must achieve 
high levels of sensitivity, equivalent to low limits of detection. Stringent specificity is also 
required to ensure accurate discrimination among the abundance of biomolecules found in a 
sample. These levels of performance must be maintained in heterogeneous samples such as 
the complex biological matrices of blood, urine and saliva, a requirement that adds a 
significant challenge in light of the need to overcome nonspecific binding. Furthermore, to 
enable routine use of diagnostic test results, rapid turnaround on the timescale of a physician 
office visit (~20 minutes) is highly desirable.
The enzyme-linked immunosorbent assay (ELISA) is the laboratory workhorse technology 
for protein biomarker detection14. This technique, which uses an antibody sandwich assay 
format, can achieve clinically relevant levels of specificity and accurately report on levels of 
a target protein analyte. However, because of the technique’s moderate (picomolar) 
sensitivity, it fails to detect even lower, but potentially clinically relevant levels of 
biomarkers often found in many samples of interest (for example, femtomolar to attomolar 
concentrations). Indeed, many potential markers of cancer, cardiovascular disease and 
neurodegenerative disease are present at these low levels in affected patients. A grand 
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challenge for the protein detection field has thus been to improve sensitivity dramatically 
relative to the picomolar sensitivity of ELISA. Assays carried out on solid surfaces or in a 
laminar flow format concentrate the signal required for readout into a specific area; 
however, the target molecules in a sample must come into direct contact for a binding event 
to take place. This type of two-dimensional approach becomes limited by the slow diffusion 
of biomolecules.
The polymerase chain reaction (PCR), along with other enzymatic amplification methods 
that copy target molecules until they can be detected by fluorescence or other macroscale 
techniques, is the present-day gold standard for nucleic acid analysis15. The sensitivity and 
specificity of PCR allow detection at single-digit copy numbers and specificity at the single-
nucleotide level. The level of automation for PCR-based assays achieved in several 
commercial platforms has enabled moderate-complexity labs to conduct sophisticated 
molecular diagnostic testing. However, the multiple-hours turnaround times and the need for 
lab skills to obtain accurate answers with PCR assays have not allowed them to be used in 
point-of-care settings.
For molecular diagnostics to extend their reach into the clinic, complete, sample-to-answer 
test automation will be required. This penetration to the clinic will demand short turnaround 
times compatible with physician office workflow. Achieving these capabilities is 
particularly important for indications such as infectious disease where the spread and 
severity of an infection can be limited with a rapid diagnosis. Therefore, any new nucleic 
acid biosensing technologies must be simple, fast, highly sensitive and specific.
Another key challenge to bioanalysis relates to implementing protein and nucleic acid 
analysis when rare cells must be isolated from clinical samples. For example, the analysis of 
CTCs may allow for non-invasive sampling of markers that define a tumour’s phenotype 
and metastatic potential. However, these cells are present at concentrations as low as 5 cells 
per millilitre, and are therefore outnumbered by billions of normal cells in one millilitre of 
blood. Commercially available platforms for CTC immunocapture have, despite the known 
limitations that cause many types of CTC to evade detection, brought CTC enumeration into 
mainstream cancer research. Advanced platforms with improved sensitivities and expanded 
versatility (for example, capture based on new markers, or even marker-free capture) are 
required to bring CTC analysis into routine clinical cancer management.
Advances in ultrasensitive protein detection
Achieving a clinically relevant combination of sensitivity, specificity and speed in protein 
detection has recently seen rapid progress through the use of materials of different length 
scales. Nanomaterials (for example, nanoparticles) have high surface-to-volume ratios and 
their surfaces are therefore well suited for the binding of reporter groups for biomolecular 
detection assays; however, microscale materials with lower surface-to-volume ratios that 
possess a larger core of active material are better choices for manipulations such as magnetic 
capture. Hence, combining these materials to detect bioanalytes brings together features that 
promote efficient binding of target analytes while also facilitating the collection of captured 
molecules.
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A means of bringing together engineered micro- and nanoparticles for high-performance 
biomarker detection is illustrated by a class of assays that use DNA molecules as bio-
barcodes16 (Fig. 2a). Because their sequences are connected with specific analytes when the 
assay is designed, the DNA molecules serve as barcodes that report on what analyte has 
been detected. The first component of the capture is a microparticle with a magnetic core, 
and the second is a spherical nucleic acid (SNA)17. SNAs are gold nanoparticles 
functionalized with DNA molecules that can also be decorated with different functionalities, 
in this case a monoclonal antibody. Even at low concentrations, the complex can — once the 
target protein is sandwiched between the magnetic microparticle and DNA-coated gold 
nanoparticle — rapidly be isolated using a magnetic field. Subsequently, the gold 
nanoparticle conjugate that is part of the sandwich complex is rapidly dissolved, thereby 
releasing the DNA barcode strands. Mapping a specific DNA sequence onto each protein 
target of interest enables multiplexing, wherein the sequence is then detected using 
established microarray methods. The efficient capture of targets, enabled by the ability of 
the SNAs to interrogate the sample in three dimensions and combined with protein-to-DNA 
amplification, allows for femtomolar, and in some cases even attomolar, limits of detection.
This type of assay has been used for the detection of the HIV-1 p24 Gag protein, and was 
shown to have excellent analytical (Fig. 2b) and clinical (Fig. 2c) sensitivity18. Another 
example highlighting the sensitivity of this approach involved a clinical study that sought to 
correlate levels of the prostate-specific antigen (PSA) with prostate cancer recurrence in 
men post-prostatectomy19. Because the assay has a limit of detection 300 times lower than 
the most sensitive ELISA assay available commercially, it was possible to obtain accurate 
PSA measurements on patients who could then be informed that their low PSA levels were 
stable and that it was likely that their cancer would not recur. This was true for more than 
half of the patient pool; with the other half, the enhanced sensitivity allowed detection of 
increasing levels of PSA, which are linked to recurrence. The study also suggested that the 
assay could be used to monitor patient response to adjuvant or salvage therapies.
The bio-barcode strategy has also been used to track markers of Alzheimer disease in 
cerebral spinal fluid, a sample matrix in which the protein marker concentration is too low 
(<1 pM) to be detected using conventional ELISA and immunoassay technologies20. The 
assay was used to analyse the presence of amyloid-β-derived diffusible ligands (ADDLs) in 
cerebral spinal fluid from patients who had been definitively diagnosed with the disease 
post-mortem. ADDLs are potential soluble pathogenic Alzheimer disease markers. A 30-
person study showed that all subjects, both with and without Alzheimer disease, had 
measurable levels of ADDL, and that all but two of the patients with Alzheimer disease had 
statistically elevated levels of ADDL compared with samples from healthy age-matched 
controls. The ability to track levels of ADDL in cerebral spinal fluid, and potentially also in 
blood, offers a path to using precise diagnostic tools to track the responses of patients who 
have Alzheimer disease to new therapies.
Using nanoscale reporter groups combined with microscale capture agents has produced 
significant advances in the sensitivity that can be achieved for the detection of clinically 
relevant protein biomarkers. This capability will be useful in a clinical context to monitor 
disease recurrence and to utilize biomarkers that are present at very low levels. An 
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interesting and important question remains open and of interest to this field: what is the 
lowest concentration at which clinically relevant biomarkers can be present in patient 
samples? Since most biomarker discovery efforts are performed with very small samples, it 
remains possible that rare, yet highly specific biomarkers, could be missed in light of 
today’s sensitivity limits. As discovery methods turn up rarer molecules, diagnostic 
technologies will be required to continue to analyse ever larger samples and further improve 
detection limits.
Nucleic acid detection with record-breaking speed
Protein biomarkers are important tools for the non-invasive screening and diagnosis of 
disease, but in many cases it is also essential to analyse nucleic acid sequences. Analysing 
genetic mutations and alterations that are implicated in cancer subtyping, bacterial antibiotic 
resistance and adverse reactions to many drugs are all examples of diagnostic applications 
where nucleic acid sequences must be delineated.
Today, the analysis of panels of nucleic acids is achieved predominantly in centralized 
laboratories. Most commercial assays rely on the enzymatic amplification of a target 
sequence, followed by readout of the amplified sequence using an optical method. A major 
unmet challenge for the field is the rapid detection of nucleic acids (that is, in under 30 
minutes) with sample-to-answer automation — an achievement that would enable analysis 
outside of sophisticated labs. Realization of this goal would provide a powerful solution for 
the diagnosis of infectious diseases and for other indications where treatment decisions are 
time sensitive.
As an alternative to nucleic acid detection approaches based on enzymatic amplification, 
strategies based on amplification-free direct detection methods have received significant 
attention as they may represent a better solution for testing outside of the laboratory 
environment. Eliminating amplification may provide a way to speed the delivery of test 
results, and also simplify assay workflow to enable straightforward automation. For 
example, several integrated circuit-based strategies have sought to use electronic 
transduction schemes for sensitive direct nucleic acid analysis. By functionalizing silicon 
nanowires with nucleic acid probes21, field-effect transistors can be made that have 
conductivities that depend on the presence of a complementary target sequence. Target 
hybridization can be monitored quantitatively using this approach as a function of time22, 
and small changes in sequence can also be detected23. These devices combine high levels of 
performance with simple electronic devices that can be mass manufactured using the same 
infrastructure leveraged by the consumer electronics industry.
Direct electrochemical readout of specific nucleic acid sequences represents another solution 
to the rapid molecular analysis challenge. Electrochemical readout differs from electronic 
readout because it uses the flow of current at the surface of a sensor to determine the 
presence or absence of an analyte, rather than detecting a change in the properties of an 
electronic material. In general, electrochemical detection schemes involve the recruitment of 
redox-active reporter groups to the surface of a sensor in response to the binding of a 
specific analyte. Several different approaches to electrochemical nucleic acid detection have 
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been pursued, including methods that use sandwich-type assays to deliver reporter 
groups24,25, enzymatic labels to produce amplified currents26,27, molecular beacon-like E-
DNA assays28,29, bio-barcode assays30 and non-covalent reporter systems31,32.
In designing electrode-based detectors for electrochemical sensing, it is particularly 
important to consider the implications of the nano-to-micro length scale. In contrast to the 
particle-based approach mentioned above, electrode sensors are tethered to a measurement 
system during target binding and therefore must employ an alternative strategy to 
thoroughly interrogate a three-dimensional sample. It is advantageous to miniaturize 
electrodes to minimize signal-to-noise, but detectors that are too small will not experience 
enough collisions with slow-moving analytes to attain high sensitivity.
Indeed, rationally engineering the structures of electrochemical sensing elements both at the 
nanometre and micrometre scales has recently been shown to enable improvements in both 
the sensitivity and speed33,34 of nucleic acid detection, permitting detection of clinically 
relevant levels (fM) of nucleic acids in 30 minutes. Patterned microelectrodes on the surface 
of a glass (Fig. 3a) or silicon chip are generated by metal electrodeposition (Fig. 3b), and 
then a finely nanostructured surface is created using a second electrodeposition step (Fig. 
3c). By creating a 100-μm sensor footprint, the latest approaches promote collisions with 
slow-moving messenger RNA (mRNA) molecules in solution, thereby removing the 
diffusional limitations of other chip-based sensors that suffer from low collisional 
frequencies35. The nanoscale roughness implemented in the coating of these large sensors 
promotes the display of probes in conformations that promote efficient binding of target 
nucleic acids35. Fundamental investigations have shown that nucleic acid probe molecules 
immobilized on nanostructured microelectrode (NME) surfaces exhibit an angle of 
deflection36 (Fig. 3d) that limits steric interactions between probes35,37, thereby enhancing 
the rate and efficiency of hybridization. The NMEs have been coupled with an 
electrocatalytic reporter strategy32 for the readout of target sequences; electrocatalysis is 
triggered when a negatively charged sequence binds to the sensor surface that in turn attracts 
a positively charged redox reporter. The electrochemical reduction of this reporter is made 
catalytic by the inclusion of a second electron acceptor that regenerates the cationic reporter.
The electrocatalytic approach permits direct analysis of mRNAs that serve as markers of 
pathogenic bacteria and associated antibiotic resistance down to concentrations as low as 1 
cell per microlitre (refs 33,38; Fig. 3e) within 30 minutes, a level of sensitivity not achieved 
previously with such fast turnaround. This strategy does not require sample clean-up, 
another feature that speeds the delivery of results36. Methods employing enzymatic 
amplification or active concentrating of samples lag behind this sample-to-answer 
turnaround time, with the commercial real-time PCR system39 possessing the highest level 
of automation typically delivering results in 2–3 hours.
Electrochemical nucleic acid analysis carried out using NMEs has also been applied to the 
quantitation of a range of analytes including small molecules and proteins40, and biomarkers 
including cancer-related gene fusions41,42 and microRNAs43. In view of its low limit of 
detection, the strategy also shows promise in the analysis of gene expression in rare CTCs 
isolated from the bloodstreams of patients with cancer44.
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DNA-based nanostructures45,46 represent another means to enhance the sensitivity of 
electrochemical nucleic acid detection. Tetrahedral structures made of DNA 
oligonucleotides display probes with well-defined distances to promote accessibility and 
overall detection sensitivity (Fig. 3f). Attomolar concentrations of microRNAs were 
detected using this approach47,48, indicating that the display of probe sequences on both 
organic and inorganic nanostructures produce high levels of sensitivity. Nanomolar levels of 
small-molecule and protein49 analytes can also be detected using sensors based on DNA 
nanostructures50.
While advances in multi-length-scale engineering have improved the sensitivity and speed 
of nucleic acid detection, key challenges that remain include the demonstration of the 
robustness of direct nucleic acid detection strategies in a clinical setting and to evaluate 
whether the diverse range of biological backgrounds encountered in clinical samples will 
interfere with approaches where trace levels of specific sequences are recruited to 
electrochemical sensors. While eliminating front-end sample processing of biological 
samples simplifies the instrumentation required significantly, it renders the requirement of 
excellent specificity and sensitivity even more stringent.
High-accuracy digital biomolecular quantitation
While the methods discussed thus far are fast, sensitive and highly specific, there are limits 
to their capacity to quantitate biological analytes accurately over a large dynamic range of 
concentration. Several technologies have been developed recently that implement 
digital51,52 methods to address the quantitation challenge. In the digital approach, 
macroscopic patient samples, typically possessing millilitre to microlitre volumes, are 
subdivided into many much smaller subvolumes, typically in the nanolitre to picolitre 
range11,53,54. Dividing samples in this manner ensures that, on average, only a small integer 
number of target molecules exist within each compartment52. As a result, the occupancy of 
compartments may be described using Poisson statistics, ideally in such a way that each 
compartment contains either zero or one molecule of the target analyte (Fig. 4a). Nucleic 
acid amplification of the contents of these subvolumes can be used to provide either a binary 
outcome (hence the digital nomenclature), and the concentration of the target analyte can be 
calculated from this measured distribution. In principle, digital approaches provide a wide 
dynamic range in the determination of target concentrations compared with traditional bulk 
ensemble measurements. The size of the compartments can be varied across the micro- to 
millilitre length scales to provide an expanded dynamic range.
Microfluidic implementation of this approach has enabled quantitative biomolecular analysis 
for a variety of applications. Genetic alterations known as copy-number variations can be 
monitored to understand how individual patients respond to cancer drugs55, viral nucleic 
acids can be quantitated for infectious disease monitoring56,57, and single-cell gene 
expression profiling can be carried out to facilitate the identification of biological 
heterogeneity58. It has also been utilized to quantify unequal expression of the two copies of 
each gene found in the diploid human genome52 and profile low levels of residual disease 
biomarkers that may remain after cancer treatment55,59. In prenatal diagnostics, it can 
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provide non-invasive detection of genetic defects60,61, an approach complementary to 
advanced sequencing strategies62.
Digital amplification may also provide an effective solution for the quantification of nucleic 
acid targets in limited-resource settings — such as a remote clinic, in the field, home or any 
other location where the sophisticated equipment required for PCR is unavailable. Making 
reliable, quantitative measurements using cost-effective devices will require merging simple 
microfluidic approaches for sample preparation with amplification strategies that are 
straightforward to implement. Equipment-free compartmentalization of molecules63–66 is a 
microfluidic strategy particularly appropriate for limited-resource settings, as it eliminates 
the need for pumps. Furthermore, isothermal amplification chemistry also simplifies the 
workflow needed to detect nucleic targets by removing the requirement for thermocycling 
and is a good candidate for lab-free testing. Technologies combining these approaches have 
been validated in initial studies, wherein viral nucleic acids of HIV and the hepatitis C virus 
were partitioned in microcompartments, quantified and equivalence was shown between 
PCR and isothermal amplification chemistries64,65 (Fig. 4b). These studies were performed 
using a ‘SlipChip’, a glass substrate patterned with microcompartments of varying sizes that 
can be filled with sample and amplification reagents via relative rotation of a similarly 
patterned substrate.
Robustness, that is, consistent performance despite variation in external conditions, is a 
crucial requirement in low-resource settings and one of the key advantages of digital single-
molecule counting approaches67. Because of its reliance on binary outputs, the digital format 
gives isothermal amplification chemistries an unexpected high degree of robustness with 
respect to perturbations in temperature64, reaction time and imaging quality. Digital 
isothermal assays have been read using a mobile phone camera that captures an image of a 
chip and transmits the pattern of the positive and negative compartments wirelessly to a 
cloud server for analysis67.
A recently reported approach that uses microwells, rather than microfluidics, also applies the 
same digital logic to detect proteins68–70. Here, micrometre-sized magnetic beads with a 
capture antibody bound to their surface are added to a patient sample (Fig. 5a,b). Because 
the number of beads added exceeds the number of molecules in the sample by nearly an 
order of magnitude, the molecules bind to the beads as described by a Poisson distribution69. 
Most beads do not capture any molecules while about 10% will capture only a single 
molecule70. As in ELISA, a sandwich is formed in which the protein bridges the capture and 
detection antibodies, and thus any bead that has captured the target of interest carries an 
enzyme. The beads are then distributed into 40-femtolitre microwells, with each microwell 
sized to fit a single bead. A fluorogenic substrate is added to the bead-loaded microwell 
array and fluorescent product accumulates in wells containing an enzyme. Quantitation of 
the number of the original target protein molecules is thus obtained by counting the number 
of fluorescent wells. Femtomolar concentrations of an analyte within a sample can be 
detected, compared with low picomolar (pM) detection limits for the best commercial 
protein assays using the same reagents.
Kelley et al. Page 9









This single-molecule-array strategy can also be used to detect synthetic nucleic acids present 
at femtomolar concentrations without the need for target amplification71, and was also 
adapted to detect bacterial DNA at attomolar levels72. The approach has also been used to 
detect tau protein in samples from patients with Alzheimer disease73 and brain injury74. The 
resulting data, when combined with measurements of Abeta42 levels, can predict cognitive 
outcome after brain hypoxia due to myocardial infarction75,76. The strategy has also been 
employed to detect toxins77, to detect early HIV infection78, to predict recurrence of prostate 
cancer76,79, and to measure inflammatory markers in patients with Crohn disease80. The 
digital ELISA method has also been used to measure the low (pg ml−1) levels of PSA in 
patients with prostate cancer who have undergone radical prostatectomies — these levels 
cannot be measured with a conventional ELISA79 (Fig. 5c).
The quantitative nature of digital approaches brings new precision to the measurement of 
disease-related biomarkers, and enriches the precision of information content that can be 
obtained with clinical samples. It will enable biomolecular markers to be detected and 
monitored, thereby allowing response to therapy to be followed, and disease progression to 
be tracked accurately. However, clinical interpretation of the results will be more 
complicated and greater clinical validation may be required for the implementation of new 
quantitative tests that are currently performed on a qualitative basis.
Highly efficient capture and analysis of rare cancer cells
While molecular biomarker detection is integral to effective clinical diagnostic technologies, 
another important set of challenges relates to the capture and analysis of specific types of 
intact cell. The concentration of CTCs in the bloodstream of patients who have cancer as 
well as phenotypic status offers important information that may provide valuable diagnostic 
and prognostic insights. For this application, attaining high levels of sensitivity and 
specificity is a challenge. CTCs can be present at very low levels in blood (1–10 cells per 
millilitre), and are overwhelmingly outnumbered by normal blood cells a billion-fold.
Early technologies developed for CTC isolation and enumeration relied on tagging cells 
with magnetic nanoparticles displaying an antibody specific for the epithelial cell adhesion 
molecule (EpCAM), which is a marker present on the surfaces of many cancer cells81. 
CellSearch, an instrument approved by the Food and Drug Administration for monitoring 
treatment efficacy using this approach, is considered by many to be the present-day gold 
standard for CTC counting. While the analytical performance of CellSearch as assessed 
using cell lines is reasonable (with a reported analytical sensitivity of 1 CTC in a 7.5-ml 
sample), it typically identifies CTCs in the bloodstream for less than 50% of patients with 
cancer with metastatic disease82. As a result, it is primarily used only as a prognostic tool.
A first step in advancing next-generation CTC systems was to improve the efficiency of 
capture in patient samples. Sophisticated microfluidic devices that feature EpCAM-coated 
surfaces have proven to be effective for non-destructive CTC capture83,84. By displaying a 
nanoscale capture agent, for example an antibody to EpCAM, on a microfluidic device, 
capture efficiencies increased significantly and led to CTC detection sensitivities in patient 
samples that were improved by a factor of 2–3 times relative to CellSearch. The utility of 
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these microfluidic devices has been shown for monitoring prostate cancer84,85 and the 
identification of potential drug targets based on expression profiling of CTCs in pancreatic 
cancer86. Microfluidics-enabled strategies that rely on differences in deformability87, size88 
or density89 of CTCs relative to other cells in the bloodstream have also been developed for 
the sensitive isolation of rare CTCs. Affinity-based methods for isolating and separating 
cells remain powerful tools in light of the heterogeneity of CTCs and the possibility that 
only certain subpopulations may be clinically relevant90,91. The use of antibody cocktails to 
capture both the epithelial and mesenchymal phenotypes of CTCs showed the first 
demonstration of the epithelial-to-mesenchymal transition in patients with breast cancer92.
Work on advanced CTC capture systems has increasingly focused on expanding the types of 
surface marker that are used for cell selection. Recently, several CTC capture systems have 
been reported that can use markers other than EpCAM for capture and/or analysis93, or that 
rely on negative selection so that a priori knowledge of the surface expression 
characteristics of CTCs is not required94. For example a microfluidic inertial focusing 
platform — the iCTC chip (Fig. 6a,b) — combines several types of separation95. It depletes 
smaller red blood cells and platelets in the first microfluidic stage using a mechanical filter. 
The system then allows CTCs and leukocytes to be sorted using either positive or negative 
selection via the attachment of magnetic microparticles to the remaining cells, and a 
magnetic field directs the cells to different isolation chambers. For positive selection of 
CTCs, a marker such as EpCAM can be used to bind magnetic beads to CTCs for isolation, 
while for negative selection, leukocyctes and granulocytes can be labelled with a cocktail of 
antibodies to separate them from the CTCs. This approach was shown to be effective with 
patient samples having low CTC loads. For samples where <30 CTCs were detected in a 
7.5-ml sample using the iChip, CellSearch often did not report any CTCs (Fig. 6c).
An additional recent study documented the use of a micro-Hall detector for the simultaneous 
analysis of several different markers96. This approach does not capture CTCs selectively, 
but instead identifies cells with a particular marker profile in an unpurified sample, thereby 
avoiding the loss of cells, which is often incurred in purification. Magnetic nanoparticles 
with varying magnetization properties are functionalized with different antibodies to surface 
antigens, and the presence of specific particles is analysed with a micro-Hall detector. This 
approach increased CTC detection frequency in patient samples by 25% over what could be 
achieved with CellSearch. Another recent study documented a highly versatile ensemble-
decision aliquot ranking approach in which any antibody of choice can be employed to 
analyse the marker profile of a CTC97. Multiple antibodies are labelled with different 
flurophores, incubated with CTC-containing blood, and the sample is pumped through a 
microfluidic channel, where fluorescent cells are counted. This system also outperformed 
CellSearch and detected CTCs in 82 out of 90 patients with stage-IV metastatic breast 
cancer (91%), while CellSearch only detected cells in 44% of the patients.
Significant progress has been made in the isolation and analysis of CTCs and promising 
advances that combine microscale engineering with nanoscale binding events are on the 
horizon. Advanced methods for intracellular RNA expression may play an important role in 
CTC characterization. Engineered nanoparticles coated with oligonucleotide probes, for 
example, can enter cells, bind to an mRNA sequence of interest and concomitantly release a 
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fluorophore-labelled sequence98. This has the potential to search for CTCs based on unique 
genetic signatures.
Future frontiers for biomolecular detection technologies
Progress towards sensitive, specific, rapid, automated diagnostics has been brisk and 
impressive; nevertheless, significant opportunities to address more fully the goals of this 
field still exist, and multi-length-scale engineering is likely to remain important. The degree 
of automation varies from platform to platform, and typically is less complete in more 
complex assays. Full automation of biomolecular detection platforms will broaden the 
uptake of new detection capabilities and promote efficiency in resource-constrained 
laboratories. Better sample processing interfaces that introduce samples into analysis 
platforms with a high level of automation will facilitate the generation of accurate results 
even in the absence of highly trained operators. The platforms discussed above often focus 
on the automation of key elements of the sample processing chain (for example, automated 
sample processing or readout), but ultimately retain manual steps to connect them. An 
automated workflow with no human intervention between the introduction of a sample and 
data presentation is the goal for most assays so that they can be used outside of laboratory 
facilities.
Furthermore, although much progress has been made in multiplexing, with the technologies 
reviewed here finding successful application in the detection and even quantitation of 
multiple biomarkers, further advances are needed. It is projected that research into genetic 
fingerprints of disease will produce a demand for tests employing hundreds of biomarkers. 
In addition, tools for pre-clinical research that seek to enable the discovery and winnowing 
down of new gene expression fingerprints will benefit from rapid, automated and low-cost 
analysis of thousands of markers from libraries of prospective targets. Technologies that 
scale to this order of biomarker multiplexing will be in demand, and given the importance of 
miniaturized diagnostic devices, combinations of micro- and nanofabrication will be an 
important tool.
Conclusions
Knowledge of the molecular basis of disease is advancing rapidly, with molecular targets 
emerging in many disease states that represent promising targets for earlier detection and 
targeted treatment. As summarized in this Review, technologies that can detect and 
quantitate protein and nucleic acid biomarkers with the desired level of accuracy, cost and 
automation will be critical for the integration of these markers into routine clinical practice. 
The advances highlighted herein all perform at high levels because they leverage the 
advantages of working on several length scales to achieve high levels of sensitivity and 
specificity. Uniting features of both nano- and microscale materials brings together 
compelling capabilities for analyte capture and analysis, and combining microdevices with 
materials that allow for tagging of molecules and cells at the nanoscale has yielded devices 
with superior performance. These advances provide new means of searching for the markers 
of cancer, and neurodegenerative and infectious diseases.
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Figure 1. Length scales of interest for biomolecular detection
Bioanalytical detection approaches monitor binding events between analytes of interest and 
specific receptors that occur on the nanoscale. Nanomaterials are ideal for biomolecular 
display because their dimensions approach the molecular scale, which promotes binding 
behaviour similar to that observed in solution-based processes. For reference, a molecule of 
cholesterol is shown on the left; this molecule is nanometre-sized. A DNA molecule (red/
blue) and a protein molecule (green/blue), both structures that have sizes on the order of tens 
of nanometres are also depicted. A bacteriophage (purple), bacterial cell (green) and human 
cell (pink/blue) span the hundreds of nanometres to micrometre length scale. The microscale 
length regime is also important for biomolecular detection because most large molecules can 
only diffuse micrometres while detection is in progress. Devices can straightforwardly be 
engineered on this length scale, which facilitates the analysis of cells and processing of 
macroscale clinical samples (depicted as a test tube).
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Figure 2. The bio-barcode assay combines micro- and nanoparticles for biomolecular detection
a, A protein target (green diamond) is bound by a magnetic microparticle (grey) 
functionalized with a specific antibody (green Y-shape). The microparticles are probed with 
gold nanoparticles (yellow) that are functionalized with antibodies (green) and barcode 
sequences (blue). After isolation, the barcodes are released and detected on an array. The 
pattern of barcode binding on the array displaying a variety of barcode-binding sequences 
reports on the presence or absence of particular analytes. The same approach can be used to 
detect specific DNA sequences (bottom). b, Data showing HIV p24 Gag protein is detected 
at picogram levels using the bio-barcode assay described in a. nc, noncomplementary 
control. Error bars represent standard deviations. c, Clinical data showing sensitivity and 
specificity of the bio-barcode assay as compared to the gold standard (PCR). The x-axis 
values correspond to levels of HIV RNA in blood samples drawn from 146 patients 
measured by PCR. The y axis displays p24 protein concentrations in these same specimens 
measured by the new barcode assay. Each red dot represents a data point collected from a 
patient sample, and grey bars indicate the median and interquartile range. This data set 
shows excellent correspondence between the gold-standard PCR method used to detect HIV 
RNA and the new barcode assay that measures p24 protein, and there is strong statistical 
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significance of the data for positive versus negative patients. Panels b,c reproduced with 
permission from ref. 18, © 2008 Future Medicine Ltd.
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Figure 3. Advances in rapid nucleic acid detection based on micro-to-nanoscale engineering of 
electrode properties
a, A lithographically patterned chip that serves as a substrate for the patterning of 
nanostructured microelectrodes (NMEs). b, NMEs combine the advantage of a large surface 
area with a finely nanostructured surface. Gold is electroplated on the surface of the chip 
through apertures etched in a passivation layer. Probe molecules (blue lines) are attached to 
the electrodes, and after a target-containing sample (red lines) is introduced, reporter groups 
are incubated with the sensor to give an electrochemical readout. c, Electron micrographs 
showing NMEs have 100-μm footprints (top), but feature nanoscale roughness on the order 
of 10 nm (bottom). d, Nanoscale roughness promotes the creation of a deflection angle that 
decreases steric interference between probe molecules (blue) immobilized with a thiolated 
tether (black) on a highly nanostructured surface (orange). The grey ovals represent the zone 
within which the probe strand has additional space to interact with a target sequence because 
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of the deflection angle. e, Achievement of rapid nucleic acid detection. Data collected when 
different concentrations of bacterial lysates were incubated with NMEs with 10, 30 and 100 
μm footprint for 30 minutes. While all the sensors showed measureable levels of current 
change (ΔI) when lysates containing a high (150 cells per microlitre; black bars) level of 
bacteria were introduced, only the largest 100 μm sensors could detect the lower (1.5 cells 
per microlitre; grey bars) concentration of bacteria, illustrating the importance of the 
microscale footprint of the sensor. Error bars represent standard error values. f, DNA 
nanostructures enhance the electrochemical detection sensitivity of nucleic acids. DNA 
tetrahedral display capture probes with well-defined nanoscale spacing, and target sequences 
are read-out using an enzymatic label. Figures adapted with permission from: b,d, ref. 33, © 
2011 American Chemical Society; c, ref. 37, © 2009 American Chemical Society; e,f, ref. 
48, 2012 Nature Publishing Group.
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Figure 4. Dividing samples into nano- to femtolitre volumes allows highly accurate quantitation 
of clinically relevant targets
a, In digital single-molecule amplification, target molecules (blue and red) are 
compartmentalized into smaller volumes. Nucleic acid amplification of the targets in a much 
smaller volume than during bulk amplification gives a signal that rises above the 
background level and above the signal arising from non-specific amplification. The 
quantitation of positive and negative wells allows a highly precise ratio of two analytes to be 
determined. This approach provides a wider dynamic range than traditional bulk ensemble 
measurements when determining the concentrations of target molecules. b, Quantitation of 
viral RNA within a SlipChip microfluidic device containing wells of different sizes via 
reverse transcription and PCR. A SlipChip is a piece of plastic or glass patterned with an 
array of microcompartments that can be filled with sample, and then using a similarly 
patterned top plate, amplification reagents can be introduced into each well by slipping the 
position of the two substrates. After the amplification is complete, fluorescent products 
(green) can be detected visually, and the number of positive wells reports on the 
concentration of a target analyte. At very low concentrations of RNA, the large wells have a 
higher probability of capturing and amplifying a molecule of RNA (larger green spots). At 
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high concentrations of RNA, small wells capture and amplify RNA (small green spots). 
Quantification is performed over the range of concentrations from where several large wells 
turn green up to where several small wells remain dark. Panel b is reproduced with 
permission from ref. 64, © 2011 American Chemical Society.
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Figure 5. Microwells separate analytes into femtolitre compartments for quantitative protein 
detection
a, A target antigen incubated with magnetic beads (blue circle) binds to capture antibodies 
(orange Y shape) on the bead surface. Biotinylated detection antibodies and an enzymatic 
reporter (β-galactosidase in this case) form a sandwich complex. b, Once deposited in an 
array of microwells, a fluorescent substrate is added to the sample, and wells are quantitated 
to analyse levels of protein biomarkers. c, Analysis of clinical samples for PSA levels. 
Concentrations of PSA were measured in serum samples from patients who had undergone a 
radical prostatectomy (blue circles), healthy control samples (red squares) and Bio-Rad PSA 
control samples (black triangles) determined using a digital ELISA. All samples yielded 
levels above the detection limit of the digital method (red line). In contrast, the detection 
limit of a commercially available ELISA test (green line) is too high to provide comparable 
data. Panel c is reproduced from ref. 68, 2010 Nature Publishing Group.
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Figure 6. Advanced microdevices for circulating tumour cell isolation
a, CTCs (green) are recognized by antibody-functionalized magnetic particles (MNPs; 
grey). b, A microengineered CTC isolation chip allows negative and positive selection for 
CTCs by manipulating the flow of microparticle-tagged cells. Whole blood is injected into 
the device, and passed through an array of microposts that separate the cells based on size. 
This allows white blood cells (WBCs) and CTCs to be separated from abundant red blood 
cells (RBCs). Either the WBCs or CTCs can be labelled with magnetic particles, and the 
application of a magnetic force (B) then forces the different cells to exit the chip via 
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different outlets where they can be isolated as an enriched population. c, CTC levels isolated 
from blood samples collected from patients with metastatic breast, prostate, pancreatic, 
colorectal, or lung cancer. The samples were analysed with the iChip or the gold-standard 
CellSearch method. Significantly higher levels of CTCs were observed when the iChip was 
used, and many samples that appear negative for CTCs when CellSearch was used for 
analysis were found to have significant levels of cancer cells with the iChip. This indicates 
that CTC counting is much more accurate with this new approach and enables CTC 
monitoring even in patients with low counts. Panels b,c adapted from ref. 95, © 2013 
American Association for the Advancement of Science.
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